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Anticonvulsant drug (AED) treatment in epileptic children should be optimized 
through the anticipation of AED effectiveness at the beginning of the treatment. 
Researchers thought that the complex EEG analysis should identify the AED 
treatment’s output in children with epilepsy. The research purpose is to study the 
different EEG pattern bases on AED treatment. A total of 43 patients with ages 
of 3–9 years were studied. Three EEGs’ registration took place: before valproic 
acid-depakin (Dep) treatment, second (3 months), and third (6 months) after 
treatment. The background EEG pattern was investigated as a quantitative [abso-
lute power spectra (APs)] and brain mapping. In addition, epileptiform EEG and 
the clinical characteristics of patients were evaluated. Valproic acid reduces Aps 
in high-amplitude slow waves and spontaneous epileptic patterns decrease and 
spike-wave complex (3/s) reduces; spikes-polyspikes, sharp waves, and generalized 
paroxysms during functional tests decreased. The rhythmic monomorphic theta 
waves (RMT) of tempo-parietal region were studied using brain mapping. The 
RMT correlated with the recurrence of seizures if Dep was withdrawn. The AED 
treatment effectiveness had been shown by decreases of slow waves and suppres-
sion of epileptiform EEG pattern and clinical improvement. The effective AED 
therapy should consider the analysis of the base EEG pattern, power spectra, and 
EEG mapping.
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1. Introduction
Depakin is an anticonvulsant drug (AED) [1, 2] according to the International 
League Against Epilepsy (ILAE) recommendations [3, 4]. Depakin increases the 
GABA-ergic inhibition in the neuronal networks of the CNS [5]. VPA derivative 
depakine (Dep) [6] exerts a combined influence on the brain’s neurons. It increases 
the GABA content through GABA transfers inhibition, reducing the reuptake of 
GABA in the brain tissue and activating the GABA receptors. [5].
The EEG study during Dep treatment depends on the form of epilepsy [7]. 
EEG investigation in pediatric population during Dep treatment should be con-
sidered as a better approach [8–10] as brain malination is not completed [11–13]. 
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Moreover, nowadays no data base analysis is done to study the correlation between 
EEG and AED treatment [14]. Another problem is that there are more data on the 
EEG morphology compared to the quantitative EEG analysis [15–18].
A quantitative analysis of the EEG should reflect the effectiveness of the 
AED treatment since the EEG disorders are connected with clinical exacerbation 
[14, 19–21]. Thus, this work’s purpose is to investigate the alteration of EEG in 
epileptic children during AED treatment.
2. Materials and methods
2.1 Epileptic children
Forty-three patients with ages of 3–9 years and with different forms of epilepsy 
were recruited. Three EEGs’ registration took place: before treatment, second 
(3 months), and third (6 months) after treatment with valproic acid-depakin 
(Dep), 30–50 mg/kg treatment. They appealed at the Center of Experimental 
Biomedicene.
The diagnosis was done based on the International Classification of Epilepsy 
and Syndromes [4], clinical history, and neurological and MRI investigations. 
Classification of patients by seizure types and epileptic syndromes accurately 
identified the patients at risk for Dep-exacerbated epilepsy [22, 23]. Study involved 
both EEG and clinical analyses. Patients were characterized for the Dep dose, type 
and frequency of seizures, and EEG and Dep plasma levels [24, 25], both before 
and during the treatment. Out of 45 patients who received treatment, three of 
them developed undesirable effects. Although the physician adjusted the Dep dose, 
it did not improve the clinical outcome in two patients. Thus, these patients were 
excluded from the study. In summary, the present study included only 43 children 
of 3–9 years of age (Table 1).
The EEG investigation followed international performance standards [26] as 
part of the prescribed therapy plan. This plan was also approved by the parents and 
institutional ethics committee.
2.2 The EEG recording and methods of analysis
All patients underwent EEG recording three times: once—before administration 
of Dep (first visit) and twice—during Dep treatment, (i) 3–4 months later (the 
second visit) and (ii) 6–8 months later (the third visit).
The EEG registration was done with closed and open eyes. Functional test was 
performed with rhythmic photostimulation; hyperventilation and registration were 
ended with closed eyes. The duration of registration was 35–55 min.
The EEG signals were digitally recorded using a set of 19 scalp electrodes accord-
ing to the International 10–20 system [26] and ENCEPHALAN 131–03, professional 
version “MEDICOM.”
For an individual patient, a 10 s, artifact-free EEG pattern was analyzed.
A qualitative assessment of the EEG characteristics was performed in accor-
dance of the age standards [27].
A quantitative EEG pattern of signal processing and the power spectrum was 
obtained for each lead. The spectral analysis was used to calculate the absolute value 
[28] of power (AVP, μV^2s) within six frequency bands: delta (0.5–4.0 Hz), theta-1 
(4.0–6.0 Hz), theta-2 (6.0–8.0 Hz), alpha (8–13 Hz), beta-1 (13–24 Hz), and beta-2 
(24–50.8 Hz) (Figure 1).
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Alpha, beta, delta, and theta frequency bands were characterized by the wave 
amplitude, stability, and domination area.
Brain topography was conducted for the quantitative study.





 Age (year) 4.3 ± 1.1
 Range 2.00–5.37








  ABS 14
  TN 5
  CL 7
  TN-CL 8
 PS
  SPS 2
  CPS 3










 Focal (sharp waves, spikes, SW, etc.) 5
 PSG 5
GS: generalize seizure; ABS: absence; SPS: simple partial seizure; CPS: complex partial Seizure; and PSG: partial, 






Statistical significance for each endpoint measures was assessed using Mann–
Whitney U-test (BIOSTAT). The data obtained before treatment served as a 
baseline for assessing the dynamics of EEG characteristics during treatment. Thus, 
each subject served as its own control in the evaluation of EEG during treatment. 
Figure 1. 
Dynamics of absolute values of power spectra (AVP) at different stages of treatment. Summarizes results 
obtained from the quantitative analysis of the EEG dynamics, total of AVP (TAVP), and below the AVP of 
different frequency bands. X-line: F-frontal, C-central, T-temporal, O-occipital, and P-parietal regions of 
the brain cortex. Black columns—before treatment, shaded columns—3 months, and white columns—6 months 
after the initiation of Dep treatment. Y-line: power value—μV^2s.
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The changes in the EEG characteristics were assessed using Wilcoxon signed-ranks 
test [29]. The significance was set at p < 0.05.
3. Results
EEG before administration of Dep can be described as the deceleration of the 
background EEG due to augmentation of the high-amplitude poly- and monomor-
phic waves within the low-frequency range. Quantitative spectral analysis (brain 
mapping) of interictal EEG revealed that, in the total EEG spectrum, the most 
dominant are the oscillations of 3–8 Hz with a prevalent amplitude of 60–120 μv.
Dep reduced the amplitude in the low-frequency range (p < 0.05).
3.1 Qualitative EEG study
The qualitative analysis revealed that the Dep therapy reduced the number 
of spontaneous paroxysmal discharge (by 76%) in the resting EEG and sup-
pressed primarily the typical epileptiform complexes of spike-waves (SW) (3/s) 
(absence) [30, 31].
3.2 Quantitative EEG study
The quantitative analysis showed reduction of frequency (p < 0.05).
The Aps dynamics revealed the reduction of the incidence of low-frequency 
waves (p < 0.05), especially this effect was more prominent for the theta range.
Following the initial reduction of APs’ alpha activity, especially in the occipital 
region (p < 0.05), this index did not show any further decline (p < 0.05).
Dep treatment produced a decreased brain activity within the range of beta 
(p < 0.05) [32].
The presence of a rhythmic monomorphic mid−/high-amplitude theta waves 
despite clinical improvements (seizure-free and no epileptiform EEG correlates) 
can provoke seizures after the Dep withdrawal. Seizures recurred due to not only 
Dep withdrawal but also due to dose reduction in patients. This aggravation of 
epilepsy was found in 64% of patients [33–35]. The rhythmic monomorphic mid−/
high-amplitude theta waves can be observed using brain mapping and power 
spectra. Such a pattern is not visible in the visual EEG observation.
Dep therapy did not show a EEG clinical aggravation that was diagnosed with 
the criteria of Genton and McMenamin [33].
Dep treatment decreased the number of seizures. The clinical signs and EEG 













33 (80%) 8 (18%) 1 (2%) 42
No clinical change number (%) 1 (2%) 1
Clinical aggravation number (%)
Total number (%) 33 (80%) 8 (18%) 2 (3%) 43
Table 2. 




Antiepileptic therapy in children can be optimized via the anticipation of 
the efficacy of AED during the early stages of therapy. Since EEG provides rich 
information about the brain activity, we hypothesized that the comprehensive 
EEG evaluation during Dep therapy in the children with epilepsy can be a sensitive 
indicator of the efficacy of the treatment.
Dep therapy induced decreases of APs of low-frequency waves, which is an 
indicator of reducing of CNS excitation. Dep reduces beta bends in the posterior 
lobes, which is related with the CNS dysfunction [32].
Dep reduces spike-waves (3/s), which is related to the absence of epilepsy that 
is triggered from the thalamocortical pathway. Dep was considered as an effective 
drug in such cases [31, 36, 37].
Dep does not have an effect on irregular single spike-wave complexes, 
sharp waves, spikes-polyspikes, and paroxysmal bursts provoked by func-
tional trials. These cases reflect certain specificity of epileptogenesis [7, 38]. 
Dep differently acts on the generation of epileptiform elements with various 
morphologies—particularly, it suppresses SW complexes (3/s) but does not 
have a good effect on irregular single spike-wave complexes, sharp waves, 
and spikes. Such a picture allows us to suggest the differences in the morphol-
ogy of epileptiform elements that may reflect different neurophysiological 
and neurochemical mechanisms [3, 7, 39]. Revealing of selectivity represents 
certain theoretical and practical interests as it can serve as an indirect evi-
dence of assumptions in the genesis of various epileptiform EEG elements and 
accordingly different types of epileptic attacks [39, 40]. Other researchers like 
Truccolo et al. [41] apparently pay attention to the morphological pictures of 
background EEG [13].
VPA was shown different activity and is not effective of any type of epilepsy 
[38]. The possibility of Dep treatment of non-epileptic paroxysmal conditions in 
children and adolescents [42–45] and the investigation of children with partial 
epilepsy during carbamazepine (CBZ) treatment were described in our previous 
investigation [46].
Brain mapping revealed the essential prognostic value of morphology of the 
theta waves and its distribution upon the cortical surface. The EEG pattern was 
revealed before treatment initiation and was persistent during Dep therapy. The 
presence of rhythmic monomorphic mid-/high-amplitude theta waves on the EEG, 
especially of the temporoparietal regions, despite clinical improvements (seizure-
free and no epileptiform EEG correlates) may suggest the possible recurrence 
of seizures after withdrawal of Dep. Not only withdrawal but even reduction of 
doses can lead to a recommencement of the attacks in this group of patients. Such a 
feature of VPA suggests that its antiepileptic effect is achieved via neurophysiologi-
cal and molecular mechanisms, which partly differ from the action mechanisms of 
other AEDs [33, 34]. Analysis of basic characteristics of EEG during the treatment 
suggests that the rhythmic monomorphic mid−/high-amplitude theta waves are 
predicting signs of aggravation. Such an EEG pattern is revealed based on the evalu-
ation of background EEG characteristics, spectral analysis, and EEG mapping using 
a quantitative EEG approach.
AED treatment should be done under a regular EEG control due to aggravation 
of the EEG pattern, which sometimes predicts the clinical signs of exacerbation 
[47, 48].
Reduction of slow wave concomitant with decreases of epileptiform pattern and 
clinical signs at 3 months after DEP treatment suggests that the treatment is effec-
tive in these cases [49].
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5. Conclusions
The EEG study suggests that the presence of rhythmic monomorphic theta 
waves with the tempo-parietal region should anticipate the recurrence of epilepsy 
in children with epilepsy, if the Dep dose would be reduced or if the Dep therapy 
would be withdrawn. The efficacy of Dep treatment should be correlated with 
decreases of high amplitude, low frequency, and suppression of epileptiform EEG 
parallel to the clinical improvement. Thus, optimal therapy suggests of evalua-
tion of baseline EEG, power spectra, and brain topography mapping using EEG 
methods.
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